Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.
Dow Jones Industrial Average
) is trading up 85 points (+0.5%) at 17,715 as of Wednesday, Jul 29, 2015, 10:36 a.m. ET. During this time, 80.1 million shares of the 30 Dow components have changed hands vs. an average daily trading volume of 329.8 million. The NYSE advances/declines ratio sits at 1,844 issues advancing vs. 1,027 declining with 195 unchanged.
- EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
The Dow component leading the way higher looks to be
), which is sporting a 56-cent gain (+1.6%) bringing the stock to $35.91. This single gain is lifting the Dow Jones Industrial Average by 4.24 points or roughly accounting for 5% of the Dow's overall gain. Volume for Pfizer currently sits at 13.9 million shares traded vs. an average daily trading volume of 21.8 million shares.
Pfizer has a market cap of $211.45 billion and is part of the health care sector and drugs industry. Shares are up 13.5% year-to-date as of Tuesday's close. The stock's dividend yield sits at 3.3%.
Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells healthcare products worldwide.
TheStreet Ratings rates Pfizer as a
. The company's strengths can be seen in multiple areas, such as its solid stock price performance, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, expanding profit margins and growth in earnings per share. We feel its strengths outweigh the fact that the company has had somewhat disappointing return on equity.
- You can view the full Pfizer Ratings Report.